Analytical Method Development for related substances (Organic impurities) in Pharmaceuticals: A Comprehensive review of Methodologies and Regulatory Compliance
Sumeet Dwivedi, Rajesh Kumar Chawla, Naresh Ambekar · European journal of parenteral & pharmaceutical sciences · 2025
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
European journal of parenteral & pharmaceutical sciences · OpenAlex · article · 2025
Abstract
The terms "related substances" and "organic impurities" are fundamental and often used interchangeably within the pharmaceutical landscape, referring to any component in a drug substance or drug product that deviates from the intended active pharmaceutical ingredient (API) or its excipients. The stringent control of these entities is not merely a regulatory compliance exercise but a critical determinant of patient safety, therapeutic efficacy, and overall product quality.
This comprehensive review provides an in-depth, methodical exploration of the analytical method development process specifically tailored for these impurities, with a pronounced emphasis on High-Performance Liquid Chromatography (HPLC) due to its unparalleled versatility and quantitative precision. We meticulously dissect the foundational regulatory architecture provided by key international bodies, including the International Council for Harmonisation (ICH) guidelines (Q3A, Q3B, and Q6A), in conjunction with the stringent requirements mandated by the United States Pharmacopeia (USP) and the U.S. Food and Drug Administration (FDA).
The document elucidates a systematic methodology for method creation, spanning from the initial investigative literature review and meticulous sample preparation to advanced chromatographic optimization techniques. A significant portion is dedicated to the indispensable role of forced degradation studies in engineering a truly stability-indicating method, one capable of discerning and quantifying impurities arising throughout a drug's lifecycle. Through detailed practical applications and case studies for both drug substances and finished drug products, we illustrate the intricate calculations of impurity levels and the rigorous, multi-faceted process of method validation.
Furthermore, the review candidly addresses prevalent challenges encountered in impurity analysis, such as co-elution, the elusive nature of unknown impurities, and matrix interferences, offering robust solutions often leveraging cutting-edge analytical technologies like LC-MS/MS. The report concludes by casting a forward-looking gaze on the future trajectory of impurity analysis, underscoring the transformative impact of Ultra-High-Performance Liquid Chromatography (UHPLC), high-resolution mass spectrometry, and the overarching principles of Quality by Design (QbD) in shaping the next generation of pharmaceutical quality control.
Open the resolved locator · 10.37521/ejpps30407
Metadata licence: OpenAlex metadata (CC0)